Obesity in the spotlight

Assessing big Pharma vs. small-to-mid-cap bios

Last month, we reported on various new oral obesity treatments and provided an assessment of the competitive landscape surrounding the GLP-1 market. Today, we will cover what drug classes are shaping up to be the foundation of obesity, what drugs have the most promising weight loss data, and how smaller innovators can challenge the big pharma incumbent…